Domestic to global BioDerm’s established presence in over 20 countries and a diverse product line spanning urinary management, securement, skin protection, and adhesive removal presents cross-sell opportunities to international distributors and hospital networks seeking standardized, proven hydrocolloid solutions.

Hospital and homecare growth There is a clear demand path from institutional settings to homecare, driven by Men’s Liberty Acute and Men’s Liberty external catheter solutions that reduce CAUTI risk and daily device changes, suggesting sales plays targeting hospitals, long-term care, and home health agencies.

D2C and expansion Recent D2C initiatives for UriCap Female indicate a strategic push direct to patients; leverage these channels to upsell complementary BioDerm devices and securement products through caregiver and patient education initiatives.

Operational optimization Notable headcount reduction and ceasing local plant operations signal the need for new distribution strategies, channel optimization, and partnerships to maintain supply continuity while controlling costs—an opportunity to position BioDerm as a lean, reliable supplier to distributors and healthcare networks.

Strategic partnerships Past investments from Abacus and Mountaingate plus ongoing regulatory-friendly product lines (FDA-cleared TheraSafe and CAUTI-reducing solutions) create openings for co-marketing with distributors, contract manufacturers, and healthcare systems seeking innovative, evidence-backed medical devices.